Vivoryon Therapeutics NV (STU:05Y) Q3 2024 Earnings Call Highlights: Strategic Shifts and ...

In This Article:

  • R&D Expenses: EUR 12.6 million for the first nine months of 2024, up from EUR 10.4 million in the same period of 2023.

  • G&A Expenses: EUR 4.9 million for the first nine months of 2024, down from EUR 6.8 million in the same period of 2023.

  • Net Loss: EUR 17.4 million for the first nine months of 2024, unchanged from the same period in 2023.

  • Cash and Cash Equivalents: EUR 12.5 million as of September 30, 2024, compared to EUR 28.6 million as of December 31, 2023.

Release Date: December 10, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Vivoryon Therapeutics NV (STU:05Y) reported positive kidney function data from the VIVA-MIND Phase 2 study, showing significant improvement in eGFR versus placebo.

  • The company presented kidney outcome results at ASN Kidney Week, receiving positive feedback from the nephrology community.

  • Vivoryon hosted a virtual kidney disease KOL event, highlighting the potential of varoglutamstat in addressing key inflammatory and fibrotic pathways in kidney disease.

  • The company plans to start a Phase 2 study in diabetic kidney disease (DKD) in 2025, leveraging strong data from VIVIAD and VIVA-MIND studies.

  • Vivoryon has extended its financial guidance, expecting cash and cash equivalents to fund operations into the third quarter of 2025.

Negative Points

  • Vivoryon reported a net loss of EUR17.4 million for the first nine months of 2024, consistent with the same period in 2023.

  • The company's cash and cash equivalents decreased significantly from EUR28.6 million at the end of 2023 to EUR12.5 million as of September 30, 2024.

  • The VIVA-MIND study was terminated early due to lack of efficacy in Alzheimer's disease, impacting the planned patient enrollment.

  • There is a need for additional funding and partnerships to support future clinical studies and potential expansion into orphan kidney diseases.

  • The company faces challenges in maintaining momentum in Alzheimer's research due to the shift in focus towards kidney disease.

Q & A Highlights

Q: Can we expect any additional sub-analysis from the VIVA-MIND study or any additional data on transforming levels or weight loss topic blood pressure? A: We are at the beginning of the analysis of VIVA-MIND and will take our time to thoroughly analyze the data. We plan to publish and disclose additional findings in the next webcast or press release. Regarding diabetic kidney disease, we still need to conduct some analysis, but given the overall positive results, we expect similar outcomes.